Korean J Obes 2014; 23(3): 150-155
Published online September 30, 2014
Copyright © Korean Society for the Study of Obesity.
Department of Biochemistry-Molecular Biology1, School of Medicine, Eulji University, Daejoen; Department of Internal Medicine2, Division of Endocrinology, Eulji University Hospital, Daejeon, Korea
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Currently used biomarkers in metabolic diseases are neither sufficient for monitoring the stage of disease development nor for monitoring differences among patients with different underlying pathogenetic pathways and pathogenesis. Exosomes and microvesicles, which are released from a wide variety of tissues, cells and blood cells in response to normal or stressed state, and under pathogenic conditions, contain various proteins, mRNAs, miRNAs and etc. that reflect the diverse functional and dysfunctional states of the releasing cells and tissues. Therefore, exosomes and microvesicles could be the next potential new biomarkers that could help predict, diagnose, treat and monitor prognosis of metabolic diseases as in obesity. Exosomes and microvesicles may overcome limitations of current biomarkers once their characteristics are clarified and methods for easier detection are developed.
Keywords: Exosomes, Microvesicles, Biomarkers, Metabolic diseases